A型和B型肉毒杆菌毒素的商业制剂及处理
Commercial preparations and handling of botulinum toxin type A and type B.
作者信息
Parish Jennifer L
机构信息
Department of Dermatology and Cutaneous Biology, Jefferson Medical College of Thomas Jefferson University, 1760 Market Street, Philadelphia, PA 19103, USA.
出版信息
Clin Dermatol. 2003 Nov-Dec;21(6):481-4. doi: 10.1016/j.clindermatol.2003.11.009.
The recognition of botulinum toxin as a therapeutic tool has revolutionized the approach to facial esthetics. In the 1970s, Dr. Alan B. Scott pioneered the use of botulinum toxin type A (BTX-A) for strabismus. This discovery led to further studies examining other clinical applications of BTX-A and, more recently, botulinum toxin type B (BTX-B). Despite its widespread use and the more than two decades of experience with BTX-A, controversy remains over the preparation and handling of the toxin.
肉毒杆菌毒素作为一种治疗手段的认可彻底改变了面部美学的治疗方法。20世纪70年代，艾伦·B·斯科特博士率先将A型肉毒杆菌毒素（BTX-A）用于治疗斜视。这一发现促使人们进一步研究BTX-A的其他临床应用，以及最近的B型肉毒杆菌毒素（BTX-B）。尽管BTX-A已被广泛使用且有二十多年的应用经验，但关于该毒素的制备和处理仍存在争议。
Zotero 插件